May 11, 2026 – CanSino Biologics Inc. (hereinafter referred to as “ CanSino Biologics ” , 688185.SH , 06185.HK ) announced that its independently developed adsorbed acellular diphtheria-tetanus-diphtheria-tetanus combined vaccine ( for individuals aged 6 years and older) (hereinafter referred to as “ Td5cp for adolescents and adults ” ) has been officially included in the priority review list by the National Medical Products Administration ( NMPA ). With the accelerated review and approval process, this product, as an important part of the company's comprehensive DPT protection system throughout the entire life cycle, is expected to fill the gap in DPT booster immunization products for individuals aged 6 years and older in China, helping to build a broader and stronger immune barrier.

Pertussis is an acute respiratory infectious disease caused by Bordetella pertussis, and it is highly contagious . ¹ In recent years, pertussis has shown a resurgence globally. In 2024 , China reported more than 470,000 cases of pertussis ,¹ an increase of approximately 12 times compared to 2023 , and the situation regarding disease prevention and control continues to receive attention.

Against this backdrop, the importance of booster immunizations for adolescents and adults is increasingly prominent, in addition to basic immunizations for infants and young children. Currently, DPT vaccination remains one of the most effective means of preventing pertussis, but there has long been a lack of systemic booster immunization products for people over 6 years old in China. The Td5cp for adolescents and adults included in this priority review is an innovative product launched based on disease trends and upgraded immunization strategies, and it is expected to further improve the immunization protection system for all age groups.

In April of this year , the company's adsorbed acellular pertussis (three-component) diphtheria-tetanus combined vaccine for infants and young children — Pankangxin® ( DT3cP for infants and young children )—was approved for marketing through the priority review channel of the National Medical Products Administration, marking a significant breakthrough in China's innovative technology path for component-based pertussis-tetanus vaccines. Compared to the three-component (pertussis toxin PT antigen, filamentous hemagglutinin FHA antigen, and pertussis adhesin PRN antigen) DT3cP for infants and young children , the five-component Td5cp for adolescents and adults adds FIM2 and FIM3 antigens and achieves separate purification and precise proportioning of each pertussis antigen, thereby further improving product quality stability and batch-to-batch consistency . The advancement of this product will also promote the application of component-based pertussis-tetanus combined vaccine technology to a wider range of age groups.

With the Td5cp vaccine for adolescents and adults entering the priority review process, the company's DPT vaccine product portfolio is rapidly taking shape. In the future, this product is expected to synergize with the already approved DT3cP Pancon® for infants and young children , gradually building a DPT immunization system covering the entire life cycle of infants, adolescents, and adults.

CanSino Biologics continues to focus on the needs of infectious disease prevention and control, advancing technological innovation and product iteration around key diseases such as meningitis, pneumonia, and pertussis. Leveraging the synergistic development of multiple technology platforms, the company is accelerating the construction of an internationally competitive innovative vaccine R&D and production system. Looking ahead, the company will continue to strengthen its technological leadership in the field of innovative bacterial vaccines, providing more innovative vaccine products to support the prevention and control of key infectious diseases and the construction of a full life-cycle immunization system in my country.
https://mp.weixin.qq.com/s/a-Lhpp276dwLQ8wcYLBsOw